Ramucirumab: First Global Approval

Ramucirumab (Cyramza™ [US]), a fully human immunoglobulin G1 (IgG1) monoclonal antibody that inhibits vascular endothelial growth factor receptor-2 (VEGFR-2), has been developed by Eli Lilly (formerly ImClone Systems) for the treatment of cancer. Ramucirumab has received its first global approval in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drugs (New York, N.Y.) N.Y.), 2014-06, Vol.74 (9), p.1047-1058
Hauptverfasser:	Poole, Raewyn M., Vaidya, Asha
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Adenocarcinoma - pathology Agreements Angiogenesis Antibodies, Monoclonal - chemistry Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Antineoplastic agents Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Blood vessels Chemotherapy Disease Progression Drug Approval Drug Screening Assays, Antitumor Esophageal Neoplasms - drug therapy Esophageal Neoplasms - pathology Esophagogastric Junction - drug effects Esophagogastric Junction - pathology Gastric cancer General aspects Humans Hypertension Internal Medicine Kinases Libraries Ligands Medical prognosis Medical sciences Medicine Medicine & Public Health Metastasis Monoclonal antibodies Pharmacology. Drug treatments Pharmacology/Toxicology Pharmacotherapy Pharmacy Proteins R&D Insight Report Ramucirumab Stomach Neoplasms - drug therapy Stomach Neoplasms - pathology Tumors Urine Vascular endothelial growth factor Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Ramucirumab (Cyramza™ [US]), a fully human immunoglobulin G1 (IgG1) monoclonal antibody that inhibits vascular endothelial growth factor receptor-2 (VEGFR-2), has been developed by Eli Lilly (formerly ImClone Systems) for the treatment of cancer. Ramucirumab has received its first global approval in the US for use as monotherapy in the treatment of advanced or metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma in patients who experience disease progression on or after fluoropyrimidine- or platinum-containing chemotherapy. Ramucirumab is the first treatment to be approved by the US FDA for this setting. This article summarizes the milestones in the development of ramucirumab leading to this first approval for the treatment of gastric cancer and gastro-oesophageal junction adenocarcinoma.
ISSN:	0012-6667 1179-1950
DOI:	10.1007/s40265-014-0244-2